For example, Spry1 and Spry2 levels are decreased in prostate and breast cancer, whereas downregulation of Spry2 has been described in hepatocellular carcinoma, B-cell lymphoma, or endometrial carcinoma, among others [17]. Here, SPRY2 is linked to hepatocellular carcinoma.